Athira Pharma (NASDAQ:LONA) Posts Earnings Results, Misses Estimates By $0.27 EPS

Athira Pharma (NASDAQ:LONA – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.27), Zacks reports.

Athira Pharma Trading Down 6.9%

Shares of Athira Pharma stock traded down $0.24 during mid-day trading on Monday, hitting $3.23. 58,395 shares of the stock were exchanged, compared to its average volume of 94,635. The stock has a market capitalization of $30.34 million, a price-to-earnings ratio of -0.77 and a beta of 1.90. Athira Pharma has a twelve month low of $2.21 and a twelve month high of $14.21. The company has a 50-day simple moving average of $5.34 and a 200 day simple moving average of $7.53.

Analyst Ratings Changes

A number of research firms have commented on LONA. Wall Street Zen raised Athira Pharma to a “hold” rating in a report on Saturday, October 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Athira Pharma in a research note on Wednesday, November 4th. Mizuho reduced their price objective on Athira Pharma from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Wednesday, August 19th. Finally, Citizens Jmp reduced their price objective on Athira Pharma from $18.00 to $17.00 and set a “market outperform” rating for the company in a report on Monday, August 17th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Athira Pharma currently has an average rating of “Moderate Buy” and an average target price of $17.33.

Read Our Latest Research Report on Athira Pharma

Athira Pharma Company Profile

(Get Free Report)

Athira Pharma is a clinical-stage biopharmaceutical company based in Bothell, Washington, that focused on developing treatments for neurodegenerative diseases and other conditions affecting the brain. Its research centered on the hepatocyte growth factor (HGF) and MET biological system, which is involved in neuronal health and repair. The company’s pipeline included fosgonimeton, an investigational therapy studied for Alzheimer’s disease and dementia associated with Parkinson’s disease, as well as ATH-1105, a small-molecule candidate investigated for amyotrophic lateral sclerosis.

Read More

Earnings History for Athira Pharma (NASDAQ:LONA)

Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.